Abstract
Background: Poor linear growth and pubertal delay, both common in children with HIV (CWH) in sub-Saharan Africa, may affect adolescent bone accrual and future fragility fracture risk. We investigated the association of HIV with size-adjusted bone density in peri-pubertal children in Zimbabwe.
Methods: CWH aged 8-16 years taking ART for ≥2 years from public-sector HIV clinics in Harare, and HIV-uninfected children from schools in the same suburbs, were recruited into a cross-sectional study. Sociodemographic, clinical and anthropometric data were collected. The prevalence of dual-energy X-ray absorptiometry (DXA) measured bone outcomes, total-body less-head bone mineral content-for-lean mass adjusted for height (TBLH-BMCLBM) and lumbar spine bone mineral apparent density (LS-BMAD), were determined. Linear regression models, using multiple imputation for missing data, assessed relationships between risk factors and TBLH-BMCLBM and LS-BMAD Z-scores.
Findings: We recruited 303 CWH and 306 without HIV, mean (SD) age 12.5 (2.5) years and 50% female. Median ART duration was 8.1 (IQR 6.2-9.5) years; for 102 (34%) ART included tenofovir disproxil fumarate (TDF). Compared to children without HIV, those with HIV had higher prevalence of TBLH-BMCLBM (10.4% vs. 6.2%, p=0.066) and LS-BMAD Z-Scores <-2 (14.3% vs. 5.8%, p=0.001). HIV and male sex were associated with earlier Tanner stage. The negative associations between HIV and both TBLH-BMCLBM and LS-BMAD were more pronounced with pubertal maturation, particularly in females. Among CWH, years of TDF exposure and orphanhood were associated with lower TBLH-BMCLBM Z-Score. Current TDF use (v.s., non-TDF containing ART) was associated with a reduction in TBLH-BMCLBM and LS-BMAD Z-Scores of 0.41 (95%CI 0.08, 0.74; p=0.015) and 0.31 (0.08, 0.69; p=0.116) respectively.Interpretation: Despite ART, HIV is associated with substantial skeletal deficits towards the end of puberty. The size of bone deficits associated with TDF and its widespread use in children in sub-Saharan Africa raise concern for future adult fracture risk.
Methods: CWH aged 8-16 years taking ART for ≥2 years from public-sector HIV clinics in Harare, and HIV-uninfected children from schools in the same suburbs, were recruited into a cross-sectional study. Sociodemographic, clinical and anthropometric data were collected. The prevalence of dual-energy X-ray absorptiometry (DXA) measured bone outcomes, total-body less-head bone mineral content-for-lean mass adjusted for height (TBLH-BMCLBM) and lumbar spine bone mineral apparent density (LS-BMAD), were determined. Linear regression models, using multiple imputation for missing data, assessed relationships between risk factors and TBLH-BMCLBM and LS-BMAD Z-scores.
Findings: We recruited 303 CWH and 306 without HIV, mean (SD) age 12.5 (2.5) years and 50% female. Median ART duration was 8.1 (IQR 6.2-9.5) years; for 102 (34%) ART included tenofovir disproxil fumarate (TDF). Compared to children without HIV, those with HIV had higher prevalence of TBLH-BMCLBM (10.4% vs. 6.2%, p=0.066) and LS-BMAD Z-Scores <-2 (14.3% vs. 5.8%, p=0.001). HIV and male sex were associated with earlier Tanner stage. The negative associations between HIV and both TBLH-BMCLBM and LS-BMAD were more pronounced with pubertal maturation, particularly in females. Among CWH, years of TDF exposure and orphanhood were associated with lower TBLH-BMCLBM Z-Score. Current TDF use (v.s., non-TDF containing ART) was associated with a reduction in TBLH-BMCLBM and LS-BMAD Z-Scores of 0.41 (95%CI 0.08, 0.74; p=0.015) and 0.31 (0.08, 0.69; p=0.116) respectively.Interpretation: Despite ART, HIV is associated with substantial skeletal deficits towards the end of puberty. The size of bone deficits associated with TDF and its widespread use in children in sub-Saharan Africa raise concern for future adult fracture risk.
| Original language | English |
|---|---|
| Article number | 569-581 |
| Pages (from-to) | 569-581 |
| Number of pages | 13 |
| Journal | Lancet Child and Adolescent Health |
| Volume | 5 |
| Issue number | 8 |
| Early online date | 14 Jun 2021 |
| DOIs | |
| Publication status | Published - 1 Aug 2021 |
Bibliographical note
Funding Information:RR ( grant number 206764/Z/17/Z ) and RAF ( grant number 206316/Z/17/Z ) are funded by the Wellcome Trust . CM-K is funded by a National Institute of Health Fogarty Trent Fellowship. AMR is partially supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the European and Developing Countries Clinical Trials Partnership 2 programme supported by the EU ( grant number MR/R010161/1 ). All other authors declare no competing interests.
Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- bone density
- stunting
- HIV
- children
- antiretroviral therapy
- tenofovir disoproxil fumarate
- Africa
Fingerprint
Dive into the research topics of 'Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver